A subanalysis was performed on data acquired from 67 subjects having serum cholesterol levels of 6.2 mmol/l or above (≧ 240 mg/dl) and triglyceride levels of 2.25 to 4.00 mmol/l (199–354 mg/dl) (excluding patients with familial hypercholesterolemia) who were participating in a multi center study comparing lovastatin and gemfibrozil, to evaluate the role of these agents in the treatment of combined hyperlipidemia (type lib phenotype). In stratum 1 (cholesterol measures of 6.2-7.79 mmol/l [240-301 mg/dl]), patients received either lovastatin 20 mg nightly (n=17) or gemfibrozil 600 mg twice daily (n=8), and in stratum 2 (cholesterol levels ≧ 7.8 mmol/l [≧ 302 mg/dl]), patients received either lovastatin 40 mg nightly (n=23) or gemfibrozil 600 mg b.i.d. (n=19) for 6 weeks. Low-density lipoprotein (LDL) cholesterol levels were reduced significantly more by lovastatin than by gemfibrozil (stratum 1,-23 versus +1% stratum 2, -34 versus -12% respectively). A treatment goal of 4.0 mmol/l (155 mg/dl) for LDL cholesterol was achieved by 59 and 35% of patients receiving lovastatin and by 0 and 11% of patients receiving gemfibrozil in strata 1 and 2, respectively. Gemfibrozil was more effective
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً